Market Report · July 16, 2026
Report Feature
Oral Biologic & Biosimilar Drug Trends and Forecast
The future of the global oral biologic & biosimilar drug market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets. The global oral biologic & biosimilar drug market is expected to grow with a CAGR of 13.6% from 2024 to 2030. The major drivers for this market are rising demand for advanced biologic treatments, increasing cases of chronic diseases, and rapid advancement in biotechnology.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Oral Biologic & Biosimilar Drug by Segment
The study includes a forecast for the global oral biologic & biosimilar drug by therapy, disease, molecule type, distribution channel, and region.Oral Biologic & Biosimilar Drug Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:
• Lymphocyte Modulators
• Interleukin Inhibitors
• Tumor Necrosis Factor-Alpha Inhibitors
Oral Biologic & Biosimilar Drug Market by Disease [Shipment Analysis by Value from 2018 to 2030]:
• Asthma
• Crohn'S Disease
• Carcinoma
• Arthritis
• Diabetes
• Multiple Myeloma
• Enterocolitis
• Multiple Sclerosis
• Others
Oral Biologic & Biosimilar Drug Market by Molecule Type [Shipment Analysis by Value from 2018 to 2030]:
• Vaccines
• Proteins & Peptides
• Monoclonal Antibodies
Oral Biologic & Biosimilar Drug Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Oral Biologic & Biosimilar Drug Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Oral Biologic & Biosimilar Drug Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies oral biologic & biosimilar drug companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the oral biologic & biosimilar drug companies profiled in this report include-• Novartis
• Oramed Pharmaceuticals
• Rani Therapeutics
• Eli Lilly & Co.
• AstraZeneca
• Novo Nordisk
• Biocon
• BiosanaPharma
• Entera Bio
• Allergan
Oral Biologic & Biosimilar Drug Market Insights
Lucintel forecasts that tumor necrosis factor-alpha is expected to witness highest growth over the forecast period.Within this market, monoclonal antibodies is expected to witness highest growth over the forecast period.
North America is expected to witness highest growth over the forecast period.
Features of the Global Oral Biologic & Biosimilar Drug Market
Market Size Estimates: Oral biologic & biosimilar drug market size estimation in terms of value ($B).Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Oral biologic & biosimilar drug market size by various segments, such as by therapy, disease, molecule type, distribution channel, and region in terms of value ($B).
Regional Analysis: Oral biologic & biosimilar drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different therapies, diseases, molecule types, distribution channels, and regions for the oral biologic & biosimilar drug market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the oral biologic & biosimilar drug market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for oral biologic & biosimilar drug market?Answer: The global oral biologic & biosimilar drug market is expected to grow with a CAGR of 13.6% from 2024 to 2030.
Q2. What are the major drivers influencing the growth of the oral biologic & biosimilar drug market?
Answer: The major drivers for this market are rising demand for advanced biologic treatments, increasing cases of chronic diseases, and rapid advancement in biotechnology.
Q3. What are the major segments for oral biologic & biosimilar drug market?
Answer: The future of the oral biologic & biosimilar drug market looks promising with opportunities in the hospital pharmacy, retail pharmacy, and online pharmacy markets.
Q4. Who are the key oral biologic & biosimilar drug market companies?
Answer: Some of the key oral biologic & biosimilar drug companies are as follows:
• Novartis
• Oramed Pharmaceuticals
• Rani Therapeutics
• Eli Lilly & Co.
• AstraZeneca
• Novo Nordisk
• Biocon
• BiosanaPharma
• Entera Bio
• Allergan
Q5. Which oral biologic & biosimilar drug market segment will be the largest in future?Answer: Lucintel forecasts that tumor necrosis factor-alpha is expected to witness highest growth over the forecast period.
Q6. In oral biologic & biosimilar drug market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
Table of Contents
1. Executive Summary
6.2 Emerging Trends in the Global Oral Biologic & Biosimilar Drug Market
6.1.1 Growth Opportunities for the Global Oral Biologic & Biosimilar Drug Market by Therapy
6.1.2 Growth Opportunities for the Global Oral Biologic & Biosimilar Drug Market by Disease
6.1.3 Growth Opportunities for the Global Oral Biologic & Biosimilar Drug Market by Molecule Type
6.1.4 Growth Opportunities for the Global Oral Biologic & Biosimilar Drug Market by Distribution Channel
6.1.5 Growth Opportunities for the Global Oral Biologic & Biosimilar Drug Market by Region
Methodology
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in this market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Buy Now
Choose a license that fits your team. Instant PDF delivery.
Prices exclude taxes. Instant delivery. Custom licensing available on request.
Key Questions
- • What are some of the most promising, high-growth opportunities for the oral biologic & biosimilar drug market by therapy (lymphocyte modulators, interleukin inhibitors, and tumor necrosis factor-alpha inhibitors), disease (asthma, Crohn's disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, and others), molecule type (vaccines, proteins & peptides, and monoclonal antibodies), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- • Which segments will grow at a faster pace and why?
- • Which region will grow at a faster pace and why?
- • What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- • What are the business risks and competitive threats in this market?
- • What are the emerging trends in this market and the reasons behind them?
- • What are some of the changing demands of customers in the market?
- • What are the new developments in the market? Which companies are leading these developments?
- • Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- • What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- • What M&A activity has occurred in the last 5 years and what has its impact been on the industry? For any questions related to Oral Biologic & Biosimilar Drug Market, Oral Biologic & Biosimilar Drug Market Size, Oral Biologic & Biosimilar Drug Market Growth, Oral Biologic & Biosimilar Drug Market Analysis, Oral Biologic & Biosimilar Drug Market Report, Oral Biologic & Biosimilar Drug Market Share, Oral Biologic & Biosimilar Drug Market Trends, Oral Biologic & Biosimilar Drug Market Forecast, Oral Biologic & Biosimilar Drug Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Recommended Reports
Market Report · July 15, 2026
Needle Free Injection System Market Report: Trends, Forecast and Competitive Analysis to 2035
Read More
Market Report · July 15, 2026
